Pay in 4 interest-free payments of $5.59 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Triple-hormone-receptor agonist Retatrutide for obesity: Phase 2 trial (48-week study, up to 24% weight loss) American Diabetes Association (2023) ADA Press Release: Novel agent Retatrutide results in substantial weight reduction (83rd Scientific Sessions, Phase 2 data) ADA Meeting News (2023) Phase 2 trial results: benefits of Retatrutide in obesity, type 2 diabetes, NASH (83rd ADA Scientific Sessions coverage) ClinicalTrials.gov Study of Retatrutide (LY3437943) in adults with obesity (NCT04881760
10 : :
[PMID: 9632361] PubMed record related to this compound for laboratory literature review
The MHRA and EMA have reviewed this evidence, and the Summary of Product Characteristics (SmPC) for semaglutide (Ozempic, Wegovy) specifically advises that patients with diabetic retinopathy should be closely monitored during treatment, particularly during periods of rapid glycaemic improvement
She attributes this to the fact that younger patients might be more aware of new treatments that are available and willing to seek them out, as well as the fact that there is a stigma towards people who are obese, especially for younger people
US$ 27.92
US$ 28.51
US$ 24.87
US$ 28.33
.jpg)
US$ 23.66
US$ 28.78
US$ 28.53
US$ 28.53
